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mia time, and since the large majority of organs can be al-
located locallyor regionally,itwillalso significantlyreduce
transportationcosts. While dealing with a life-saving but
scarce medical resource, a continuous and open-minded
discussion is the only way to maintain a well-balanced
and socially acceptable equipoise between equity, utility
and efficiency.
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Global analysis of proteins
The application of proteomics (the study of protein pro-
ducts expressed by the genome) has become one of the
leading post-genomic technologies given the increased un-
derstanding of the central role of proteins and protein–pro-
tein interactions in all aspects of cellular function [2].
Systematic global identification and quantification of pro-
teins can, not only inform improved biomedical under-
standing of a particular system in healthy or diseased
individuals, but also be used for protein biomarker discov-
ery. The most popular of the many proteomic strategies
available are summarized in Figure 1 and, whilst two-
dimensional electrophoresis (2DE) gel-based approach
remains popular, liquid chromatography–tandem mass
spectrometry (LC-MS/MS) and gel electrophoresis then
liquid chromatography mass spectrometry (geLC-MS) ap-
proaches are now preferred as state-of-the-art.
Protein biomarker discovery has been a major driving
force for the field and abundant scientific evidence from
proteomics and other disciplines strongly suggests that
most, if not all, diseases will result in changes in certain
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Nephrol Dial Transplant (2010): Editorial Comments 1749Fig. 1. Strategies for the global identification and quantification of proteins. Proteins may be derived from biological fluids or solubilized from entire
cells or their subcellular fractions. One option with biological fluids is to use proprietary immunodepletion methods (A) to remove up to 20 of the most
abundant proteins in order to more readily analyse the lower abundance proteins. Following solubilization, proteins may be separated by 2DE (B). In
this workflow, an individual separated protein is removed as a gel plug, trypsin digested and the resulting peptides are typically separated on the basis of
relative hydrophobicity by nanoscale LC. The amino acid sequence of these peptides is then determined by MS/MS [19,20] and this data is used to
search existing protein databases to achieve a match and, therefore, a protein identification (ID). One can process multiple gel plugs to identify many of
the 2DE-separated proteins. The method of choice for 2DE protein quantification is DIGE (C) whereby samples are labelled with different fluorescence
dyes prior to mixing together (multiplexing) and 2DE [16]. Such gel-based proteomics remains popular, but for global analysis, it is now more
commonplace to trypsin digest the entire solubilized protein mixture to produce a peptide ‘soup’ of all the proteins in the sample (gel-free LC-MS/
MS proteomics) (D). Peptides are then separated by LC on the basis of relative hydrophobicity and often also charge as a multidimensional separation.
Then, extensive MS/MS and database searches are performed to identify many (ideally all) of the proteins in the original sample. One of the advantages
of this workflow is that it is possible to achieve simultaneous quantitative data by introducing an iTRAQ labelling step (E) (or other labelling step)
following trypsin digestion without the need for additional LC-MS/MS [17,18]. A further method for global protein identification is to first separate
proteins by one-dimensional electrophoresis (1DE) before subjecting individual protein bands to digestion and LC-MS/MS (the geLC-MS workflow)
(F). Whilst this is an excellent workflow for high numbers of protein IDs, it is not particularly amenable to protein quantification methodologies.Finally,
therearemanyotheroptions.Forexample,onemayenrichforpeptidesorproteinsofaparticulartypetostudyaparticulargroupofproteinsandthisismost
commonly performed for phosphorylation analysis. Peptide isoelectric focussing (IEF) as an additional step within the usual LC-MS/MS workflow is a
valid option for increased numbers of IDs and protein LC can also be performed prior to trypsin digestion. Finally, SELDI-TOF MS ProteinChip
technology may be potentially used for biomarker discovery, although the approach has certain limitations [21].
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usually chosen for analysis but other biological fluids will
also likely contain protein profiles indicative of homeosta-
sis or diseases in that locale or organ system. For example,
urine has been the focus of a number of studies in relation
to kidney and bladder diseases [4,5] and cerebrospinal flu-
id has also received a good deal of attention for neurolog-
ical conditions [6]. There have been very few proteomic
investigations of clinical effusion materials (pleural, peri-
cardial and peritoneal) [7] with preliminary reports on
peritoneal fluid limited to studying endometriosis [8] and
ovarian cancer [7,9].
Proteomics to study peritoneal dialysis
One of the reasons why there have been so few studies on
peritoneal effusions is that the material is not straightfor-
ward to obtain. Peritoneal dialysis (PD) is a highly effective
and convenient mode of renal replacement therapy and of-
fers the unique opportunity for access to and analysis of
peritoneal dialysis effluents (PDE) from all types of pa-
tients. Whilst not the same as peritoneal effusions, this fluid
is nonetheless a clinically relevant sample that can be ana-
lysed to provide critical information about PD specifically
as well as the peritoneal environment more generally. Sev-
eral groups have recently taken on this challenge and pro-
duced preliminary proteomics studies on PDE [1,10–14].
The paper in this edition by Wang et al. [1] is the first
study to show proteomic differences between diabetic peri-
toneal PDE and normal peritoneal fluid (five patients and
two controls). Following 2DE analysis, a number of these
proteins were confirmed by western blotting and included
vitamin D-binding protein, haptoglobin and α-2 macro-
globulin at raised levels and complement component
C4A and immunoglobulin κ at lower levels. The authors
propose that the loss of vitamin D-binding protein, hapto-
globin and α-2 macroglobulin may be due to a change in
the permeability of the peritoneal membrane to medium-
sized proteins or leakage due to peritoneal inflammation.
They also suggest that lower levels of C4A in the dialysate
may shed light on the mechanisms responsible for the ini-
tiation of peritoneal membrane scleroses. Only limited
studies on the role of immunoglobulin κ in the peritoneum
have been reported and lower levels in the dialysate may
provide a novel aspect for peritoneal change during PD
therapy. Whilst preliminary in nature, the identification
of protein differences between normal fluid and diabetic
PDE provides useful information for more detailed fol-
low-up studies.
Altered levels of C4A and immunoglobulin κ were also
revealed in the first published proteomic analysis on PDE
using a cohort of 20 chronic PD patients with varying
transport rates [12]. Following 2DE, five proteins were
identified with significantly different levels among the
transport groups. In particular, increased levels of C4A
and immunoglobulin κ in higher transport versus lower
transport patients were confirmed in a further validation
set of 24 patients by ELISA. This further emphasizes the
value in further exploring these two proteins and demon-
strates that proteomics can be used to compare differences
between different patient sub-groups.
The only other significant PD proteomic study used a
moresophisticated methodology(geLC-MS)withninepae-
diatric PD patients to identify a total of 189 PDE proteins
with 88 shared by all patients [10]. Unlike the previous
two studies, no comparisons were made between different
sample types but analysis of the protein list revealed that
the majorityof proteins identifiedwere derivedfrom theex-
tracellular matrix (84 compared with 11% plasma proteins)
reflecting the clear retention of PD fluid within the extracel-
lular space. Hence, proteomics can also potentially provide
clinically relevant information about localization of and
changes in proteins in the peritoneal membrane. There is
clear relevance here to pathological alterations in the perito-
neal membrane described in the biopsy registry study [15].
This proteome also revealed a number of new proteins such
as gelsolin and intelectin that had not been previously re-
ported in PDE. One of the exciting aspects of proteomics
technology is that it allows for the discovery of previously
unknown proteins in a particular sample which can then
lead to the generation of new hypotheses. In this case, gel-
solin has been proposed to be a marker for sepsis but in PD
might play a protective role in mesothelial cell damage and
against infection. Intelectin (also called omentin) is an adi-
pocytokine with a possible role in defence against intesti-
nal bacterial permeation and parasites and may be of
relevance to host defence in the peritoneal cavity.
Finally, two other studies have used proteomic methods
on PDE. In one study, 2DE and surface-enhanced laser
desorption/ionization mass spectrometry (SELDI-TOF
MS) were performed on PDE from 16 patients with
peritonitis and β2-microglobulin was further proposed
as a biomarker for PD peritonitis [11]. In the other study,
2DE and SELDI-TOF MS were again used and a total 21
proteins were identified from PDE but no significant con-
clusions were drawn [14].
Time now for more extended studies
The proteomic studies to date on PDE have only been very
preliminary and further prospective studies with greater
numbers of patients might enable sub-group analyses to
yield additional information about changes in peritoneal
dialysate proteins that are associated with specific pheno-
types, for example, association with membrane function,
residual renal function, nutritional status, the risk of peri-
toneal infection and fibrosis or the onset of encapsulating
peritoneal sclerosis [12]. From this, conclusions might be
directly drawn or this information could be used to inform
further more focused investigation.
The number of proteins identified in PDE studies to date
is small with only one managing over 30 proteins [10] and
many much less than this. With so many more proteins re-
mainingtobediscoveredorconfirmed,thechallengenowis
to adopt the range of workflow choices (see Figure 1) in or-
der to produce more comprehensive protein lists. Each
workflow will reveal certain unique proteins not found with
theothermethodologies;so,formaximumproteomiccover-
age, a combination of several approaches is recommended.
Whilst expensive and technically challenging, such efforts
will enable novel proteins to be identified to enable new hy-
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biomarker signatures to be more carefully investigated.
In addition better approaches are required to quantify
differences between samples and the PD field need to
adopt these. The proteomics community has largely moved
on to 2DE-based difference gel electrophoresis (DIGE)
[16] or LC-based MS labelling workflows, such as isobaric
tags for relative and absolute quantification (iTRAQ)
[17,18], as gold standards for relative protein quantifica-
tion (see Figure 1). These are more statistically robust than
2DE gel-to-gel comparison approaches used to date on
PDE and necessary for the quantification of more subtle
changes in proteins.
The Achilles’ heel of proteomics
As a note of caution, the analysis of biological fluids, in-
cluding PDE, is not straightforward. The huge potential
for biomedical and biomarker discovery is limited by the
considerable challenge of identifying the lowest abundant
proteins which may often be the most biologically relevant
or the likely source of biomarkers. In biological fluids,
there are typically well over 10 orders of magnitude differ-
ences in abundance between the most and the least abun-
dant proteins [3]. As the analytical technologies available
generally have 2–4 orders of magnitude dynamic range for
protein detection, there is clearly a shortfall and not all
proteins can currently be identified using these methods
alone.
All is not lost, however, as these technologies still do
identify proteins that have not been previously identified
in given systems and hence produce highly valuable infor-
mation. Immunodepletion methods can be used to remove
t h e2 0o rs om o s ta b u n d a n tp r o t e i n s( ∼97% of the total
protein content for plasma), but this is not sufficient to
solve the problem and additionally interesting proteins
might be lost that bind to these common proteins. There
are also certain other sample fractionation approaches that
may be employed to improve specificity, but paradigm
changes in proteomics technology will be necessary for
all proteins to be identified.
Looking to the future
Whilst preliminary in nature, the PDE proteomics studies
performed to date do reveal how proteomics can be used to
potentially further understand PD. Whilst PD replaces the
function of the kidney, pathological damage of the perito-
neum is a frequent occurrence and cannot be easily iden-
tified without invasive techniques. Proteins identified from
PDE may provide insights and facilitate the non-invasive
discovery of potential biomarkers for measuring peritoneal
damage and changes in transport. Additionally, the effect
of different dialysis fluids or the impact of infection and/or
prolonged PD duration on protein profiles might also be
investigated to provide improved understanding of the
pathological processes that remain the barrier to wider ac-
ceptance and utilization of the therapy.
Further detailed proteomics studies are now warranted
in this field and will undoubtedly provide improved bio-
medical understanding and may also lead to novel bio-
marker discovery for the diagnosis, prognosis and
therapeutic monitoring of pathological events related to
PD. Clinical proteomics is still in its infancy but does
have the potential for ‘bedside’ applications. In time,
there is every reason to believe that this technology
platform will also make key contributions to both the
understanding and utilization of PD.
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In the July 2009 issue of the journal Clinical Infectious
Diseases, the Infectious Diseases Society of America
(IDSA) published an update of their ‘Clinical Practice
Guidelines for the Diagnosis and Management of Intravas-
cular Catheter-Related Infection’ [1]. The largest part of
the IDSA text relates to non-dialysis catheters, and it is
not always clear to what extent these general recommenda-
tions can be extrapolated to the haemodialysis condition. A
specific but only brief section (∼2 pages) of the IDSA
guidelines is devoted to haemodialysis catheters.
In a position statement published in the June issue of
NDT Plus [2] by the European Renal Best Practice
(ERBP), these IDSA guidelines are amended with focus
on haemodialysis conditions. ERBP is the new guidance
body of the European Renal Association–European Dialy-
sis and Transplantation Association (ERA–EDTA) repla-
cing European Best Practice Guidelines (EBPG) since
2008. In contrast to the IDSA Guidelines, the ERBP posi-
tion statement contains not only a section on treatment but
also one on prevention and is entirely devoted to haemo-
dialysis catheters. The publication was written according to
the new philosophy of ERBP [3,4] and conforms to previ-
ously published documents [5–7].
The current editorial review offers a summary of this
monograph [2], highlighting the most relevant statements.
The reader is referred to the full text for the proper
recommendations, a more extended rationale and sever-
al dialectic reflections on the original IDSA guidelines.
At the end, the text in NDT Plus contains also a list of
research suggestions.
General: tunnelled vs non-tunnelled catheters
Central vein catheters as an access for chronic haemodia-
lysis are discouraged, in accordance with the previous
EBPG guidance [8], although they are lifesaving in a sub-
stantial proportion of the dialysed population, who have
run out of native access possibilities. If the use of a central
vein catheter seems unavoidable, preference should be giv-
en to cuffed, tunnelled catheters unless contraindications
are present, since the barrier they impose against inocula-
tion is more efficient than with non-tunnelled catheters. It
is considered mandatory to remove non-tunnelled tempo-
rary catheters as soon as possible, even in the absence of
complications, and to have them replaced preferentially by
an arteriovenous fistula (AVF), an arteriovenous graft
(AVG), or a tunnelled central vein catheter, in that order
of preference.
Prevention of infection
Catheter insertion and position
Catheters should be inserted under strict aseptic circum-
stances and according to the conditions formulated by
EBPG [8]. Due to the complication profile [9], the use
of the femoral and subclavian vein positions is discour-
aged. The right internal jugular vein is the preferred loca-
tion for insertion, followed by the left internal jugular
vein.
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